Philochem

Philochem is a discovery-focused biotech subsidiary of the Philogen group, leveraging its leadership in DNA-encoded chemical libraries and phage display to create novel targeted anti-cancer therapies. The company has demonstrated significant validation through a major licensing deal with RayzeBio/Bristol Myers Squibb for its prostate cancer radiopharmaceutical program, OncoACP3, valued at up to $1.35 billion plus royalties. With a strategy centered on ligand-based pharmacodelivery to spare healthy tissues, Philochem advances a pipeline of small molecule therapeutics, antibodies, and radiopharmaceuticals from discovery into clinical development.

Integrated discovery platform featuring DNA-Encoded Chemical Libraries (DEL), proprietary phage display libraries for fully human antibodies and cyclic peptides, chemical proteomics for target validation, and ligand-based pharmacodelivery for creating targeted therapeutics (e.g., radiopharmaceuticals, ADCs).

Philochem competes in the crowded fields of DNA-encoded library technology (vs. companies like X-Chem, DyNAbind, Vipergen) and targeted radiopharmaceuticals (vs. Novartis, Point Biopharma, Lantheus). Its integrated approach and validated success with a major pharma partner provide a competitive edge, but it faces pressure from larger, well-resourced biopharmaceutical companies with similar strategic focuses.